Oculus Innovative's Microcyn Tech could Protect Hospital's Against MRSA Outbreaks

Stephen L Kanaval  |

Oculus Innovative Sciences, Inc. (OCLS) has a very promising principal platform: Microcyn Technology. The platform can treat a wide range of pathogens and viruses including MRSA and Vancomycin-resistant Enterococcus (VRE), both of which cause chronic wounds. The Microcyn treatment has also been successfully tested on H1N1. The treatment solution for Microcyn is safe and non-irritating and validated in many clinical studies. Currently the company has 60 different Microcyn offerings and products in various markets.

OCLS has 24 patents with 100 pending around the world. The company is looking to clear Microcyn as an antimicrobial in the form of a hydrogel through the US Food and Drug Administration, but already has seven FDA approvals for wound cleaning, lubricating, moistening and dressing.

(below taken from company fact page)

The company’s other product line relates to nagging itching and minor skin irritation. After having laser treatment, many patients experience extreme inching to the contact areas. Some, and you can Google this and read accounts for yourself, as wake-me-up-in-the-middle-of-the-night itching. The real issue here is that the itching can put the treatment area at risk for healing properly, if a patient cannot control themselves or find a suitable remedy.

Oculus’ product is called Lasercyn™ and it is designed to help patient manage post-non-ablative laser therapy procedures, post-microdermabrasion therapy and following superficial chemical peels. The product can also relieve pain and itching from minor skin irritation, lacerations and minor burns. "Lasercyn is a promising new tool for all aesthetic dermatologists who are looking to better manage post-laser itch and pain associated with laser skin resurfacing, while promoting enhanced healing and protection against secondary infections. In our clinical testing of Lasercyn to date, we have seen dramatically improved outcomes with quicker healing times and less patient discomfort when Lasercyn is added to the post-procedure management protocol," said Dr. Michael Gold, a board-certified dermatologist and cosmetic surgeon out of Nashville, Tennessee who runs the Gold Skin Care Center, Advanced Aesthetics Medical Spa, The Laser & Rejuvenation Center, and Tennessee Clinical Research Center. Many people are turning away from plastic surgery to rejuvenate skin and in 2015 laser skin care rose 22%. Besides the pain of itching, the benefit of laser skin care tempts many because it is fast, low risk and affordable. With a solution from Oculus, many surgeons and skincare centers could be recommending the Lasercyn product to further coax patients into the safety of laser skin procedures.

Sign up for our Free Newsletter


DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Companies

Symbol Name Price Change % Volume
OCLS Metro Inc. n/a n/a n/a n/a

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     

INTERVIEW: CEO Dr. Martin Eaton - Heads Up Checkup

Equities.com Host & Contributor Silvia Davi interviewing CEO of Heads Up Checkup, Dr. Martin Eaton.